Risk of Pancreatic Cancer and Use of Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes: A Propensity Score-Matching Analysisopen access
- Authors
- Kim, Mee Kyoung; Han, Kyungdo; Kwon, Hyuk-Sang; Yoo, Soon Jib
- Issue Date
- Aug-2023
- Publisher
- KOREAN ENDOCRINE SOC
- Keywords
- Pancreatic carcinoma; Dipeptidyl-peptidase IV inhibitors; Diabetes mellitus; type 2
- Citation
- ENDOCRINOLOGY AND METABOLISM, v.38, no.4, pp.426 - 435
- Journal Title
- ENDOCRINOLOGY AND METABOLISM
- Volume
- 38
- Number
- 4
- Start Page
- 426
- End Page
- 435
- URI
- https://scholarworks.bwise.kr/ssu/handle/2018.sw.ssu/44661
- DOI
- 10.3803/EnM.2023.1737
- ISSN
- 2093-596X
- Abstract
- Background: The effects of dipeptidyl peptidase 4 (DPP-4) inhibitors over the course of long-term treatment remain unclear, and concerns have been raised regarding the role of DPP-4 inhibitors in carcinogenesis in the pancreas. Earlier studies of pancreatic adverse events have reported conflicting results.Methods: This study analyzed Korean National Health Insurance Service data from January 2009 to December 2012. Patients who had type 2 diabetes mellitus and took two or more oral glucose-lowering drugs (GLDs) were included. Patients prescribed DPP-4 inhibitors (n=51,482) or other GLDs (n=51,482) were matched at a 1:1 ratio using propensity score matching. The risk of pancreatic cancer was calculated using Kaplan-Meier curves and Cox proportional-hazards regression analysis.Results: During a median follow-up period of 7.95 years, 1,051 new cases of pancreatic cancer were identified. The adjusted hazard ratio (HR) for DPP-4 inhibitor use was 0.99 (95% confidence interval [CI], 0.88 to 1.12) compared with the other GLD group. In an analysis limited to cases diagnosed with pancreatic cancer during hospitalization, the adjusted HR for the use of DPP-4 inhibitors was 1.00 (95% CI, 0.86 to 1.17) compared with patients who took other GLDs. Using the other GLD group as the reference group, no trend was observed for elevated pancreatic cancer risk with increased DPP-4 inhibitor exposure.Conclusion: In this population-based cohort study, DPP-4 inhibitor use over the course of relatively long-term follow-up showed no significant association with an elevated risk of pancreatic cancer.
- Files in This Item
-
Go to Link
- Appears in
Collections - ETC > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.